tumor lysis syndrome

Obinutuzumab +/- bendamustine debulking prior to venetoclax in CLL 2:36
Obinutuzumab +/- bendamustine debulking prior to venetoclax in CLL
Jeff Sharman
Predicting TLS in venetoclax-treated CLL patients 1:43
Predicting TLS in venetoclax-treated CLL patients
Anthony Mato
U2′ regimen with checkpoint inhibition in R/R CLL and Richter’s transformation 1:37
U2′ regimen with checkpoint inhibition in R/R CLL and Richter’s transformation
Anthony Mato
Liso-Cel in CLL 4:47
Liso-Cel in CLL
Tanya Siddiqi
MRD negativity as a treatment endpoint in CLL 1:52
MRD negativity as a treatment endpoint in CLL
Arnon Kater
MURANO update: MRD, biological subsets & safety analysis 2:43
MURANO update: MRD, biological subsets & safety analysis
John Seymour
MURANO study: exciting times in CLL 2:06
MURANO study: exciting times in CLL
George Follows
Retrospective multicenter analysis of venetoclax-treated CLL patients 3:36
Retrospective multicenter analysis of venetoclax-treated CLL patients
Anthony Mato
Primary analysis of MURANO study data for R/R CLL 4:01
Primary analysis of MURANO study data for R/R CLL
John Seymour
Combination Treatment with Two Targeted Agents Shows Promise in Previously Treated CLL 8:06
Combination Treatment with Two Targeted Agents Shows Promise in Previously Treated CLL
Peter Hillmen
Managing and predicting TLS in CLL patients 1:00
Managing and predicting TLS in CLL patients
Peter Hillmen
The power of venetoclax 5:52
The power of venetoclax
Claire Dearden
BCL2 inhibition and CLL: the role of venetoclax 3:09
BCL2 inhibition and CLL: the role of venetoclax
Peter Hillmen
Why venetoclax is a promising new drug for CLL 1:34
Why venetoclax is a promising new drug for CLL
Paolo Ghia
Safety analysis of the BCL-2 inhibitor venetoclax for CLL 1:06
Safety analysis of the BCL-2 inhibitor venetoclax for CLL
Matthew Davids
Preliminary results of ibruntinib in combination with FCR chemotherapy for CLL 1:16
Preliminary results of ibruntinib in combination with FCR chemotherapy for CLL
Matthew Davids
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals